BAUSCH HEALTH COS INC (BHC) Stock Fundamental Analysis
NYSE:BHC • CA0717341071
5.95 USD
+0.02 (+0.34%)
At close: Mar 2, 2026
5.95 USD
0 (0%)
After Hours: 3/2/2026, 8:04:00 PM
Taking everything into account, BHC scores 4 out of 10 in our fundamental rating. BHC was compared to 193 industry peers in the Pharmaceuticals industry. BHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BHC is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- BHC had positive earnings in the past year.
- In the past year BHC had a positive cash flow from operations.
- In the past 5 years BHC reported 4 times negative net income.
- BHC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of BHC (0.60%) is better than 79.79% of its industry peers.
- BHC's Return On Invested Capital of 7.78% is amongst the best of the industry. BHC outperforms 87.05% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for BHC is significantly below the industry average of 12.91%.
- The 3 year average ROIC (6.89%) for BHC is below the current ROIC(7.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROIC | 7.78% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
1.3 Margins
- BHC has a better Profit Margin (1.53%) than 79.79% of its industry peers.
- BHC has a Operating Margin of 21.28%. This is amongst the best in the industry. BHC outperforms 88.60% of its industry peers.
- BHC's Operating Margin has improved in the last couple of years.
- BHC has a Gross Margin of 70.65%. This is in the better half of the industry: BHC outperforms 78.24% of its industry peers.
- BHC's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% |
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
2. Health
2.1 Basic Checks
- BHC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- BHC has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BHC has been increased compared to 5 years ago.
- Compared to 1 year ago, BHC has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.29, we must say that BHC is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.29, BHC is in line with its industry, outperforming 51.30% of the companies in the same industry.
- BHC has a debt to FCF ratio of 21.00. This is a negative value and a sign of low solvency as BHC would need 21.00 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 21.00, BHC is doing good in the industry, outperforming 77.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Altman-Z | 0.29 |
ROIC/WACC1.18
WACC6.58%
2.3 Liquidity
- A Current Ratio of 1.47 indicates that BHC should not have too much problems paying its short term obligations.
- BHC has a worse Current ratio (1.47) than 70.98% of its industry peers.
- A Quick Ratio of 1.08 indicates that BHC should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.08, BHC is not doing good in the industry: 75.65% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
- The earnings per share for BHC have decreased by 0.00% in the last year.
- Measured over the past years, BHC shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.13% on average per year.
- BHC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.66%.
- Measured over the past years, BHC shows a small growth in Revenue. The Revenue has been growing by 5.04% on average per year.
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
3.2 Future
- Based on estimates for the next years, BHC will show a decrease in Earnings Per Share. The EPS will decrease by -2.02% on average per year.
- BHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.38% yearly.
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 1.58, which indicates a rather cheap valuation of BHC.
- BHC's Price/Earnings ratio is rather cheap when compared to the industry. BHC is cheaper than 99.48% of the companies in the same industry.
- BHC is valuated cheaply when we compare the Price/Earnings ratio to 27.13, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 1.39, which indicates a rather cheap valuation of BHC.
- 98.96% of the companies in the same industry are more expensive than BHC, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.11, BHC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.58 | ||
| Fwd PE | 1.39 |
4.2 Price Multiples
- BHC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BHC is cheaper than 94.82% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, BHC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.22 | ||
| EV/EBITDA | 6.41 |
4.3 Compensation for Growth
- BHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BHC may justify a higher PE ratio.
- A cheap valuation may be justified as BHC's earnings are expected to decrease with -7.27% in the coming years.
PEG (NY)0.11
PEG (5Y)N/A
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
5. Dividend
5.1 Amount
- No dividends for BHC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.95
+0.02 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-20 2026-02-20/amc
Earnings (Next)04-28 2026-04-28
Inst Owners45.78%
Inst Owner Change-1.85%
Ins Owners10.79%
Ins Owner Change21.29%
Market Cap2.21B
Revenue(TTM)10.27B
Net Income(TTM)157.00M
Analysts48.89
Price Target7.43 (24.87%)
Short Float %1.72%
Short Ratio2.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.64%
Min EPS beat(2)-13.87%
Max EPS beat(2)2.59%
EPS beat(4)1
Avg EPS beat(4)-10.87%
Min EPS beat(4)-25.13%
Max EPS beat(4)2.59%
EPS beat(8)3
Avg EPS beat(8)-7.33%
EPS beat(12)6
Avg EPS beat(12)-4.52%
EPS beat(16)7
Avg EPS beat(16)-7.67%
Revenue beat(2)2
Avg Revenue beat(2)1.43%
Min Revenue beat(2)0.64%
Max Revenue beat(2)2.23%
Revenue beat(4)3
Avg Revenue beat(4)0.41%
Min Revenue beat(4)-1.57%
Max Revenue beat(4)2.23%
Revenue beat(8)6
Avg Revenue beat(8)0.66%
Revenue beat(12)9
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)0.16%
PT rev (1m)1.04%
PT rev (3m)2.3%
EPS NQ rev (1m)16.33%
EPS NQ rev (3m)16.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)-0.25%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1.58 | ||
| Fwd PE | 1.39 | ||
| P/S | 0.21 | ||
| P/FCF | 2.22 | ||
| P/OCF | 1.58 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.41 |
EPS(TTM)3.77
EY63.36%
EPS(NY)4.29
Fwd EY72.09%
FCF(TTM)2.68
FCFY45%
OCF(TTM)3.78
OCFY63.45%
SpS27.68
BVpS-1.49
TBVpS-44.41
PEG (NY)0.11
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.6% | ||
| ROE | N/A | ||
| ROCE | 9.85% | ||
| ROIC | 7.78% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 34.78% | ||
| OM | 21.28% | ||
| PM (TTM) | 1.53% | ||
| GM | 70.65% | ||
| FCFM | 9.67% |
ROA(3y)-0.58%
ROA(5y)-1.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)6.89%
ROIC(5y)6.18%
ROICexc(3y)7.29%
ROICexc(5y)6.47%
ROICexgc(3y)46.04%
ROICexgc(5y)39.55%
ROCE(3y)8.72%
ROCE(5y)7.82%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y7.05%
ROICexc growth 3Y16.83%
ROICexc growth 5Y15.41%
OM growth 3Y7.55%
OM growth 5Y5.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.12%
GM growth 5Y-0.37%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 21 | ||
| Debt/EBITDA | 6.08 | ||
| Cap/Depr | 33.69% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 1.42 | ||
| Cash Conversion | 41.26% | ||
| Profit Quality | 632.48% | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | 0.29 |
F-Score6
WACC6.58%
ROIC/WACC1.18
Cap/Depr(3y)27.35%
Cap/Depr(5y)23.9%
Cap/Sales(3y)3.53%
Cap/Sales(5y)3.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y6.97%
EPS 5Y-1.13%
EPS Q2Q%-4.35%
EPS Next Y13.77%
EPS Next 2Y-2.55%
EPS Next 3Y-7.27%
EPS Next 5Y-2.02%
Revenue 1Y (TTM)6.66%
Revenue growth 3Y8.11%
Revenue growth 5Y5.04%
Sales Q2Q%9.26%
Revenue Next Year4.23%
Revenue Next 2Y2%
Revenue Next 3Y-2.31%
Revenue Next 5Y-1.38%
EBIT growth 1Y17.85%
EBIT growth 3Y16.27%
EBIT growth 5Y10.72%
EBIT Next Year33.3%
EBIT Next 3Y-2.01%
EBIT Next 5Y1.07%
FCF growth 1Y-21%
FCF growth 3YN/A
FCF growth 5Y4.37%
OCF growth 1Y-12.34%
OCF growth 3YN/A
OCF growth 5Y4.73%
BAUSCH HEALTH COS INC / BHC FAQ
What is the ChartMill fundamental rating of BAUSCH HEALTH COS INC (BHC) stock?
ChartMill assigns a fundamental rating of 4 / 10 to BHC.
Can you provide the valuation status for BAUSCH HEALTH COS INC?
ChartMill assigns a valuation rating of 9 / 10 to BAUSCH HEALTH COS INC (BHC). This can be considered as Undervalued.
Can you provide the profitability details for BAUSCH HEALTH COS INC?
BAUSCH HEALTH COS INC (BHC) has a profitability rating of 6 / 10.
Can you provide the financial health for BHC stock?
The financial health rating of BAUSCH HEALTH COS INC (BHC) is 3 / 10.